Get the Stockscreener App
3.80
3.31%
-0.13
Quantum Biopharma Ltd stock is traded at $3.80, with a volume of 104.07K.
It is down -3.31% in the last 24 hours and down -46.10% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$3.93
Open:
$3.93
24h Volume:
104.07K
Relative Volume:
0.22
Market Cap:
$24.31M
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.46
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
+0.00%
1M Performance:
-46.10%
6M Performance:
-54.22%
1Y Performance:
-64.02%
1-Day Range:
$3.6386
$4.01
1-Week Range:
$3.50
$4.3982
52-Week Range:
$2.07
$15.96
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.80 | 24.31M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (NASDAQ:QNTM) - TradingView
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum BioPharma’s MS drug targets myelin as phase 2 nears - Stock Titan
Quantum BioPharma Company Profile & Introduction - Moomoo
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis - citybuzz -
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAM:0K91 - TradingView
The Quest to Repair What Multiple Sclerosis Takes Away - Caledon Enterprise
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - Sahm
Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - The Globe and Mail
Quantum BioPharma's Bid to Repair MS, Not Just Manage It - BriefGlance
Quantum BioPharma’s MS drug heads for phase 2 trials - Stock Titan
QNTM News | QUANTUM BIOPHARMA-B SUB VOT (NASDAQ:QNTM) - ChartMill
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - citybuzz -
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quantum BioPharma Ltd (QNTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quantum BioPharma Ltd (QNTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
QNTM Should I Buy - Intellectia AI
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
Quantum BioPharma Ltd (QNTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QNTM Q4 2025 Earnings: Net Loss Widens as Biotech Advances Pipeline Without RevenueCapex Guidance - lwvtexas.org
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss per Share; Stock Gains $1.78GAAP Earnings Report - newsline.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment - TradingView
CSE Filings for Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Advances Lucid-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial - citybuzz -
Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Ltd. Subordinate Voting Shares - The Canadian Securities Exchange (CSE)
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast - NewMediaWire
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - TipRanks
Quantum BioPharma Hires Stocks.news for Investor Relations Services in $250,000 Deal - citybuzz -
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate and Alcohol Metabolism Product - citybuzz -
Quantum BioPharma Hit by FDA Clinical Hold on Lead MS Drug as Director Resigns - TipRanks
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - citybuzz -
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma hires IR Agency for investor relations By Investing.com - Investing.com Australia
Quantum BioPharma Hires Stocks.news IR Agency to Boost Market Visibility - TipRanks
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - The Manila Times
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):